At its meeting in May this year, Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) will consider a listing of fedratinib (Inrebic ®) onto the Pharmaceutical Benefits Scheme (PBS) for the treatment […]
Happy new year to MPN patients and their families. Over a year ago, we publicised an article from Australian oncologist and author Dr Ranjana Srivastava, about the benefits of exercise. […]
The American Society of Hematology’s December 2024 conference included developments in treatments for MPN patients with the CalR mutation. A range of Australian and international immunotherapy research is underway and […]
In March 2025, Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) will consider an extension to the existing listing of Ruxolitinib (known as Jakavi®) onto the Pharmaceutical Benefits Scheme (PBS). The extension […]
The MAJIC-PV trial studied ruxolitinib for PV patients against best available therapy (BAT) which in this case was mainly hydroxycarbamide (hydroxyurea). It concluded that ‘ruxolitinib treatment benefits hydroxyurea intolerant or […]
The MPN AA has become aware of a warning placed on the MPN treatment Anagrelide. While haematologists would already know about the warning, and be managing patients’ treatment accordingly, the […]
This presentation by MPN specialist Dr Hans Hasselbalch from Denmark is of great interest to MPN patients. Whilst the topic is inflammation, and the importance of reducing inflammation, Dr Hasselbalch’s […]
The videos and presentations from the inspiring MPN Horizons 2024 conference in Warsaw, Poland, are now available. The conference shared the latest advancements in MPN research, treatment, and advocacy from […]
The company delivering Pegasys®, JustMeds, has advised that they are now able to deliver Pegasys® to regional patients in cold chain validated shippers. These shippers are specially made to keep […]
The company dispensing and arranging delivery for Pegasys® has set up an online ordering link to speed up the ordering process for Australian patients. This should save patients time and […]
